Clinical Trial Update: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial evaluating preoperative atezolizumab in localized head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: University Hospital, Essen | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED